Costs and Pricing

China CAR-T Insurance 2026: Price Cut to Under ¥300,000

by China Medical Services • • 7 min read

China CAR-T Insurance 2026: Price Cut to Under ¥300,000

by chinamedservices.com (China Medical Services)

China’s First CAR-T Therapy Enters National Insurance: Price Cut from ¥1.29 Million to Under ¥300,000

On November 14, 2026, China’s National Healthcare Security Administration published the 2026 National Basic Medical Insurance Drug Catalogue, and with it came the most significant CAR-T China price change to date: Carteyva (relmacabtagene autoleucel), the country’s first and currently only CAR-T therapy admitted to national basic medical insurance, saw its per-infusion price fall from ¥1,290,000 to under ¥300,000. The new price takes effect on January 1, 2027 — it is not yet in force, and no hospital can bill at the negotiated rate before that date. For Chinese enrollees, out-of-pocket costs after reimbursement may fall below ¥100,000. For international patients, the picture is different, and this article explains exactly how.

What Was Approved, and What It Treats

Carteyva is manufactured by JW Therapeutics and is a CD19-directed autologous chimeric antigen receptor T-cell therapy. Its approved indications in China cover three B-cell malignancies, all in the third-line setting — meaning patients who have already been through at least two prior lines of systemic therapy:

  • Relapsed or refractory large B-cell lymphoma
  • Relapsed or refractory follicular lymphoma
  • Relapsed or refractory mantle cell lymphoma

Third-line status matters. This is not a first-choice treatment offered at diagnosis. It is a specialized option for patients whose disease has returned or stopped responding after earlier regimens, and eligibility is determined by a hematology team reviewing the individual case, prior treatments, organ function and disease burden.

How the Price Came Down

Two forces drove the reduction. The first is domestic manufacturing. Carteyva is produced in China, including locally developed lentiviral vector production, which removes a substantial share of the imported supply-chain cost that weighs on CAR-T pricing globally. The second is the national insurance negotiation itself — the process in which manufacturers trade list price for volume access across the public insurance system.

China’s CAR-T market has operated with what industry observers describe as an informal threshold: products priced above roughly ¥500,000 were widely considered unnegotiable, and anything above ¥300,000 struggled to enter the catalogue. Carteyva’s accepted price sits just under that line. A second domestic product, nakiocabtagene autoleucel, reportedly did not enter the catalogue after its offer exceeded the ¥300,000 threshold — a useful illustration that admission was a negotiation outcome, not an automatic entitlement.

Key point: the ¥300,000 figure is the medicine price per infusion. It does not include leukapheresis, lymphodepletion conditioning, hospitalization, intensive care, or management of complications such as cytokine release syndrome. Total treatment cost is always higher than the drug price alone.

What Changes for Chinese Patients

For someone covered by China’s basic medical insurance, this is genuinely transformative. A therapy that was previously a seven-figure out-of-pocket decision moves into a range where reimbursement may bring the patient’s share below ¥100,000. That figure is an estimate for insured patients and depends on local reimbursement rules, deductibles, caps and the province where treatment occurs — provincial implementation of the national catalogue varies.

Even so, the direction is clear: CAR-T in China has shifted from a largely self-funded luxury to a partially reimbursed option for eligible insured patients. Hospitals will finalize their internal pricing and billing workflows ahead of the January 1, 2027 start date.

What It Means for International Patients — the Core Difference

Here is where we need to be direct, because this is the single most common misunderstanding we see. Foreign patients do not hold Chinese basic medical insurance. Without enrollment in the scheme, there is no reimbursement. The “under ¥100,000 out-of-pocket” number that headlines Chinese media applies to insured Chinese citizens, not to visitors.

For an international patient, the relevant CAR-T cost China figure is the negotiated medicine price of approximately ¥300,000 per infusion — plus everything around it. A realistic planning view separates those components:

Cost component What it covers How to treat it in planning
CAR-T product The infusion itself (Carteyva) ~¥300,000 per infusion at the negotiated price, subject to hospital confirmation
Leukapheresis and manufacturing Cell collection, processing, quality release Quoted separately by the treating hospital
Lymphodepletion and bridging Pre-infusion chemotherapy, disease control Varies with regimen and length of stay
Hospitalization and monitoring Ward care, ICU if required, CRS/neurotoxicity management The largest variable; request a written estimate
Evaluation, imaging, labs Eligibility workup before commitment Charged before any infusion decision

We do not publish a single all-in figure, because no responsible provider can. What we can say is that the drug price is now transparent and public, and the surrounding costs must be quoted by the hospital against a specific case. Any quote that presents “¥300,000 all-inclusive” should be treated with scepticism.

A Realistic Timeline

CAR-T is not a procedure you schedule and fly to. The sequence below reflects how evaluation and treatment generally unfold; individual timelines vary considerably with disease status and hospital capacity.

Stage Typical duration What happens
Records review and second opinion 1–3 weeks Pathology, prior regimens and imaging translated and reviewed by a hematology team
Remote consultation Days after review Discussion of eligibility, alternatives and realistic expectations
Visa and travel preparation 2–6 weeks S2 visa application with hospital supporting documents; timing depends on consulate
On-site evaluation 1–2 weeks In-person assessment, restaging, organ function, apheresis suitability
Leukapheresis and manufacturing Several weeks Cell collection, then product manufacture and release testing
Bridging therapy if needed Case-dependent Disease control while the product is prepared
Conditioning, infusion, monitoring Weeks Lymphodepletion, infusion, inpatient observation for toxicity
Early follow-up Months Response assessment and monitoring; shared with your home team

What Can Go Wrong — and What Happens Then

Honest planning requires naming the failure modes. A patient may not be eligible: prior lines of therapy, disease burden, organ function or active infection can rule out CAR-T, and that determination is made by the treating team, not by us. Manufacturing can fail or the product may not meet release specifications, which delays or cancels treatment. Cytokine release syndrome and neurotoxicity are recognized risks requiring intensive monitoring, and severe cases extend hospitalization and cost. And the 2027 price is not yet active — a patient treated in late 2026 may face different billing than one treated after January 1.

The recourse for each is procedural rather than reassuring. Eligibility uncertainty is why a written second opinion before travel matters. Manufacturing risk is why bridging plans are discussed in advance. Cost uncertainty is why a written hospital estimate, itemized, should precede any payment.

Why This Is a Genuine First

China has approved around ten CAR-T products, but until now none had entered the national basic medical insurance catalogue. Previous negotiation rounds ended without admission, largely because list prices sat far above what the scheme would accept. Carteyva’s entry is therefore a structural first: it establishes that a CAR-T product can clear the negotiation threshold in China, and it sets a reference price that later products will be measured against. Whether that leads to broader access is a policy question; what it establishes today is a precedent.

Practical Considerations for International Patients

Records come first: pathology reports, treatment history, imaging and current clinical status, translated into Chinese for hospital review. Travel for medical treatment uses the S2 visa category with supporting hospital documentation, subject to the latest consulate requirements — the M visa is for commercial and trade activity and is not the medical route. Payment at public hospitals is typically upfront with later insurance reimbursement at home, while private international hospitals may bill insurers directly. Follow-up after discharge should be planned with your home hematology team before you travel, and language support throughout an unfamiliar, very large hospital system is not optional.

Our team at China Medical Services works with 340+ top-ranked hospitals across 37 cities, and we can help identify centers with hematology and cellular therapy experience through our specialty rankings for oncology.

Frequently Asked Questions

Is the new CAR-T price available now?

No. The negotiated price takes effect on January 1, 2027. Until then, existing pricing applies. Patients planning treatment in late 2026 should confirm billing with the hospital directly.

Can foreign patients get CAR-T in China at the insured price?

No. The sub-¥100,000 out-of-pocket figure applies to Chinese basic medical insurance enrollees. International patients pay the medicine price of approximately ¥300,000 plus all associated treatment costs, quoted by the hospital for their specific case.

Is ¥300,000 the total cost?

No. It is the per-infusion medicine price only. Leukapheresis, conditioning, hospitalization, ICU care and complication management are additional and vary substantially between patients.

Your Next Step

The core message is simple: China’s CAR-T insurance breakthrough is real and significant, but it changes costs for insured Chinese patients first, and international patients should plan on the drug price plus hospital-quoted treatment costs. We are a medical navigation service — we do not provide medical advice, diagnose, or promise treatment outcomes, and we do not guarantee admission or eligibility. If you would like your records reviewed by a Chinese hematology team before making any travel commitment, you can start with a free consultation and we will explain the staged options available.

This article is for general information only and does not constitute medical advice. Treatment decisions should be made with qualified physicians who have reviewed the individual case.

For more medical information and treatment options in China, visit chinamedservices.com (China Medical Services).

Medical Disclaimer: The information provided in this article is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.

Planning medical treatment in China?

We help international patients with hospital selection, appointments, bilingual companions, and visas.

Get a Free Consultation →
China Medical Services

Chat on WhatsApp

Pick a topic to get started

What can we help you with?